Combination administration of glucocorticoid receptor modulator and CYP3A inhibitor

摘要

Applicants provide methods of treating glucocorticoid receptor modulators (GRMs) and steroidogenic inhibitors in combination and treating diseases including Cushing's syndrome and hormone-sensitive cancers with GRM and CYP3A inhibitors. The GRM can be, for example, mifepristone; the CYP3A inhibitor or steroidogenic inhibitor (collectively, "inhibitors") can be, for example, ketoconazole or itraconazole. Inhibitors can cause toxicity or other serious adverse reactions; co-administration of inhibitors with other drugs may increase the risk of such toxic and adverse reactions due to inhibitors and / or other drugs. Applicants have surprisingly found that GRM can be administered to subjects receiving inhibitors without increasing the risk of adverse reactions.